Remdesivir
- Generic Name
- Remdesivir
- Brand Names
- Veklury
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N6O8P
- CAS Number
- 1809249-37-3
- Unique Ingredient Identifier
- 3QKI37EEHE
- Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...
- Indication
Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Remdesivir Efficacy in Coronavirus Disease
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 200
- Registration Number
- NCT04345419
- Locations
- 🇪🇬
Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
- Conditions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04323761
- Locations
- 🇺🇸
Charlton Memorial Hospital, Fall River, Massachusetts, United States
🇺🇸Lawrence General Hospital, Lawrence, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 700
- Registration Number
- NCT04321616
- Locations
- 🇳🇴
Andreas Barratt-Due, Oslo, Norway
Trial of Treatments for COVID-19 in Hospitalized Adults
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-11-29
- Target Recruit Count
- 1552
- Registration Number
- NCT04315948
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Martinique, Fort De France, France
🇫🇷Centre Hospitalier Andrée Rosemon, Cayenne, France
🇫🇷CHU APHP Ambroise-Paré, Boulogne-Billancourt, France
Expanded Access Remdesivir (RDV; GS-5734™)
- Conditions
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
🇺🇸Naval Hospital Jacksonville, Jacksonville, Florida, United States
🇺🇸Benning Martin Army Community Hospital, Fort Benning, Georgia, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4891
- Registration Number
- NCT04292899
- Locations
- 🇺🇸
UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States
🇺🇸Prisma Health Richland Hospital, Columbia, South Carolina, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1113
- Registration Number
- NCT04292730
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States
🇺🇸Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Adaptive COVID-19 Treatment Trial (ACTT)
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 1062
- Registration Number
- NCT04280705
- Locations
- 🇺🇸
University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States
🇺🇸The University of Washington - Virology Research Clinic, Seattle, Washington, United States
A Trial of Remdesivir in Adults With Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 237
- Registration Number
- NCT04257656
- Locations
- 🇨🇳
Bin Cao, Beijing, Beijing, China
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 308
- Registration Number
- NCT04252664
- Locations
- 🇨🇳
Jin Yin-tan hospital, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.